Navigation Links
Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List
Date:12/2/2009

nge Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release and the section under "Financial Outlook" contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at http://www.sec.gov . Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
7. Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources
8. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
9. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2008 Results and Announces Share Repurchase
10. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
11. Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Association for Cancer Research ... ... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) announced that it presented ... at the 2008 American Association for Cancer Research (AACR),Annual Meeting. ...
... April 15, THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND ... OR PURCHASE ANY,SECURITIES REFERRED TO IN THIS ANNOUNCEMENT ... IN THE PROSPECTUS EXPECTED TO BE PUBLISHED BY,SHIRE ... PROSPECTUS WILL,BE PUBLISHED AND MADE AVAILABLE ON SHIRE,S ...
... 14 Symmetry Medical Inc.,(NYSE: SMA ), a ... industry and other medical markets, today announced that,the filing ... the Securities and,Exchange Commission will be delayed beyond its ... in the final stages and the work is,substantially completed. ...
Cached Biology Technology:ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 2ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 3ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 4ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study 5Shire to Introduce a New UK Listed Holding Company 2Shire to Introduce a New UK Listed Holding Company 3Shire to Introduce a New UK Listed Holding Company 4Shire to Introduce a New UK Listed Holding Company 5Shire to Introduce a New UK Listed Holding Company 6Shire to Introduce a New UK Listed Holding Company 7Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target 2Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target 3
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
Breaking Biology News(10 mins):Bee foraging chronically impaired by pesticide exposure: Study 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3
... ON January 27, 2014 Cancer is the ... for about 30% of all deaths, according to the ... and effective drugs, it remains extremely difficult to develop ... looked at how to leverage current experimental therapies, in ...
... from Warwick Medical School have discovered a critical point of ... cell in the human body. The study, published today ... system is a key target for cancer drugs and, as ... be made. The tracks of this so called ,railway, are ...
... researchers have discovered the process by which high-density ... becomes dysfunctional, loses its cardio-protective properties, and instead ... hardening of the arteries. Their research was published ... . The beneficial and cardio-protective properties of ...
Cached Biology News:Ottawa researchers discover new combination therapy to kill cancer 2Cracks in the cellular transport system can be key to a new generation of cancer therapies 2Cleveland Clinic researchers discover process that turns 'good cholesterol' bad 2
...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
... reagent for Virus isolation ... unique water insoluble Elastomeric ... and chaotropes; Engineered to ... viruses while preserving infectivity; ...
Integrins Sampler Kit 10g each...
Biology Products: